Long-Term Effect of Rifaximin with and without Lactulose in Minimal Hepatic Encephalopathy.
The purpose of a new study published in Digestive Diseases was to characterize active bacterial assemblages in the duodenum and feces in patients with minimal hepatic encephalopathy (MHE) before, during, and after long-term therapy with rifaximin. In this study, the gut microbiota composition of 5 patients with liver cirrhosis and MHE, who had been treated either with rifaximin 550 mg bid alone continuously for a period of 3 months or combined with lactu
To continue reading this article
Continue reading your article with a Emedinexus account..